The Latest
Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable
Questions still remain as to when FDA will approve, and how it will be implemented.
CROI 2020: What to Expect in HIV Science From This Year’s Conference
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
New Study Will Test Safety of PrEP and Dapivirine Ring in Pregnancy
While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.
NIH, Gates Foundation Hatch Plan to Develop Affordable Gene Therapy for HIV, Sickle Cell Disease
The new public-private partnership will put $200 million toward finding eventual cures for two of the world's most pervasive diseases.
IAS 2019: What to Expect in HIV Science
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups
People with college education, gay and bisexual men, and people who struggle to make clinic visits were more likely to prefer the long-acting option.
This Week in HIV Research: One Step at a Time
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Trump Administration Ends Fetal Tissue Research, Cancels Major HIV Grant
Advocates say the move is more politics than science.
This Week in HIV Research: Matters of the Heart
May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.
The Genetic Mutation Behind the Only Apparent Cure for HIV
The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?